Atorvastatin warnings and precautions: Difference between revisions
No edit summary |
No edit summary |
||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Atorvastatin}} | |||
{{CMG}} ; {{AE}} , {{PB}} | {{CMG}} ; {{AE}} , {{PB}} | ||
Skeletal muscle effects (e.g., myopathy and rhabdomyolysis): Risks increase when higher doses are used concomitantly with cyclosporine and strong CYP3A4 inhibitors (e.g., clarithromycin, itraconazole, HIV protease | Skeletal muscle effects (e.g., [[myopathy]] and [[rhabdomyolysis]]): Risks increase when higher doses are used concomitantly with [[cyclosporine]] and strong [[CYP3A4]] inhibitors (e.g., [[clarithromycin]], [[itraconazole]], HIV [[protease inhibitor]]s). Predisposing factors include advanced age (> 65), uncontrolled [[hypothyroidism]], and renal impairment. | ||
Rare cases of rhabdomyolysis with acute renal failure secondary to myoglobinuria have been reported. Advise patients to promptly report to their physician unexplained and/or persistent muscle pain, tenderness, or weakness. LIPITOR therapy should be discontinued if myopathy is diagnosed or suspected. | Rare cases of [[rhabdomyolysis]] with [[acute renal failure]] secondary to [[myoglobinuria]] have been reported. Advise patients to promptly report to their physician unexplained and/or persistent muscle pain, tenderness, or weakness. LIPITOR therapy should be discontinued if [[myopathy]] is diagnosed or suspected. | ||
Liver enzyme abnormalities: Persistent elevations in hepatic | Liver enzyme abnormalities: Persistent elevations in hepatic [[transaminase]]s can occur. Check liver enzyme tests before initiating therapy and as clinically indicated thereafter. | ||
A higher incidence of hemorrhagic stroke was seen in patients without CHD but with stroke or TIA within the previous 6 months in the LIPITOR 80 mg group vs placebo. | A higher incidence of [[hemorrhagic stroke]] was seen in patients without [[CHD]] but with [[stroke]] or [[TIA]] within the previous 6 months in the LIPITOR 80 mg group vs placebo. | ||
Revision as of 15:02, 30 January 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] ; Associate Editor(s)-in-Chief: , Pratik Bahekar, MBBS [2]
Skeletal muscle effects (e.g., myopathy and rhabdomyolysis): Risks increase when higher doses are used concomitantly with cyclosporine and strong CYP3A4 inhibitors (e.g., clarithromycin, itraconazole, HIV protease inhibitors). Predisposing factors include advanced age (> 65), uncontrolled hypothyroidism, and renal impairment.
Rare cases of rhabdomyolysis with acute renal failure secondary to myoglobinuria have been reported. Advise patients to promptly report to their physician unexplained and/or persistent muscle pain, tenderness, or weakness. LIPITOR therapy should be discontinued if myopathy is diagnosed or suspected.
Liver enzyme abnormalities: Persistent elevations in hepatic transaminases can occur. Check liver enzyme tests before initiating therapy and as clinically indicated thereafter.
A higher incidence of hemorrhagic stroke was seen in patients without CHD but with stroke or TIA within the previous 6 months in the LIPITOR 80 mg group vs placebo.